Overview

LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alberta